STOCK TITAN
  1. Home
  2. News
  3. HUGE

FSD Pharma Inc - HUGE STOCK NEWS

Welcome to our dedicated news page for FSD Pharma (Ticker: HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSD Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSD Pharma's position in the market.

News
Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
Rhea-AI Summary
FSD Pharma Inc. announced that the Court of Appeal for Ontario affirmed a judgment in the amount of CDN $2.81 million, plus $175,000, plus interest. An additional $5,000 in costs were awarded to FSD Pharma by the Court of Appeal in respect of Dr. Raza Bokhari's failed motion for leave to appeal. The judgment confirmed Arbitration Awards in which the Arbitrator dismissed Dr. Raza Bokhari's claims for wrongful dismissal, and awarded FSD Pharma its fees and costs incurred in defending the arbitration. In December 2023, FSD Pharma filed a Petition to Confirm Arbitration Awards in the United States District Court for the Eastern District of Pennsylvania.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.84%
Tags
none
-
News
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
Rhea-AI Summary
FSD Pharma Inc. welcomes Dr. Sanjiv Chopra to its board of directors, replacing Nitin Kaushal. The company has also retained the services of multiple firms to enhance market awareness and investor relations. Dr. Chopra's extensive medical background and the strategic partnerships with SBS Intl Group LLC, Draper, Inc., Carriage House Capital, Corp., IR Agency, Beyond Media, and Issuer Direct are the key highlights of the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
management
-
News
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
Rhea-AI Summary
FSD Pharma Inc. provides an update on its litigation with GBB Drink Lab, Inc., denying allegations of breach of mutual nondisclosure agreement and trade secret misappropriation. The Court denied the Motion to Dismiss, allowing FSD Pharma to proceed with discovery to demonstrate the lack of merit in GBB's claims. GBB subsequently sold its assets to Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. FSD Pharma remains confident in its decision not to acquire GBB.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
News
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC
Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) has filed a final short form base shelf prospectus to provide the Company with the flexibility to take advantage of financing opportunities and favourable market conditions, enabling the offer, issue, and sale of Securities for up to an aggregate offering amount of US$50,000,000 over a 25-month period. The Registration Statement containing a base shelf prospectus with the SEC has also been filed, allowing the offer, issue, and sale of Securities up to an aggregate amount of US$50,000,000 for a period of three years. The Company has not entered into any agreements or arrangements to authorize or offer any securities at this time, and the net proceeds from the sale of Securities will be used as outlined in the Prospectus and Registration Statement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
FSD Pharma Inc. Announces Closing of Private Placement
Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) closed a non-brokered private placement and issued 24 class A multiple voting shares at a price of $1.90 per share for gross proceeds of $45.60. The company intends to use the proceeds for general working capital purposes. Insiders, including the CEO, participated in the offering, raising concerns about related-party transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
News
FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement
Rhea-AI Summary
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) announced the closing of the proposed distribution of a portion of FSD Pharma's holdings of common shares of Celly Nutrition Corp. to certain securityholders through a statutory plan of arrangement. The distribution resulted in FSD Pharma Securityholders receiving Celly Nu Shares and New FSD Pharma Securities in exchange for their Class A Shares, Class B Shares, and FSD Pharma Distribution Warrants. The Celly Nu Shares distributed are subject to restrictions on resale until May 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness
Rhea-AI Summary
FSD Pharma Inc. (HUGE) provides an update on its litigation with GBB Drink Lab, Inc. regarding alleged breach of mutual nondisclosure agreement and trade secret misappropriation. GBB continues to intimidate competitors and critics through threats of litigation, including Capybara Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
none
-
News
FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
Rhea-AI Summary
FSD Pharma Inc. (HUGE) obtained a final order from the Ontario Superior Court of Justice approving the statutory plan of arrangement to distribute Celly Nutrition Corp. shares to FSD Pharma Securityholders. The special resolution to authorize the Arrangement was approved on November 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
News
Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
Rhea-AI Summary
Goldman Small Cap Research has published a new research report on FSD Pharma, Inc. (HUGE) highlighting its innovative biopharmaceutical products, including a patented compound for multiple sclerosis and a functional beverage for relieving the effects of alcohol consumption. The report includes a price target and emphasizes the company's potential for substantial growth and market penetration. FSD Pharma is also set to go ex-dividend on November 27, 2023, rewarding shareholders with stock in the firm launching the UNBUZZD product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
none
News
FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
Rhea-AI Summary
FSD Pharma Inc. (HUGE) has announced the approval of a plan of arrangement under which common shares in the capital of Celly Nutrition Corp. will be distributed to FSD Pharma Securityholders. The Celly Nu Shares will be distributed on November 29, 2023, subject to certain restrictions on transfer. The Arrangement is expected to close at or around the end of November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
none
Stock HUGE logo
FSD Pharma Inc

Nasdaq:HUGE

HUGE Rankings

#5147 Ranked by Market Cap
#1071 Ranked by Stock Gains
N/A Ranked by Dividends

HUGE Stock Data

24.24M
34.34M
17.37%
2.53%
0.82%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Toronto

About HUGE

fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.